PAS
ADAP

Partnervest Advisory Services’s Adaptimmune Therapeutics ADAP Stock Holding History

Partnervest Advisory Services’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-35,000
Closed -$42K – 205
2019
Q4 		$42K Buy
+35,000
New +$37.3K 0.02% 232

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Partnervest Advisory Services's ADAP Position: Q1 2020 in Review

Partnervest Advisory Services sold out of Adaptimmune Therapeutics (ADAP) in Q1 2020, closing a stake of 35,000 shares — an estimated $42K sold.

Partnervest Advisory Services first reported a position in ADAP in Q4 2019 and held it in 1 quarter. The position peaked at $42K in Q4 2019. 47 funds tracked by Wall St. Rank hold ADAP as of Q1 2020.

  • Partnervest Advisory Services reported no remaining Adaptimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Partnervest Advisory Services sold 35,000 Adaptimmune Therapeutics shares in Q1 2020, an estimated $42K.
  • Partnervest Advisory Services first reported a position in Adaptimmune Therapeutics in Q4 2019 and held it in 1 quarter.
  • Partnervest Advisory Services's Adaptimmune Therapeutics position peaked at $42K in Q4 2019.
  • 47 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2020.

Based on Partnervest Advisory Services's 13F filing for Q1 2020, filed 8 May 2020.